Skip to main content
. 2022 Jul 30;14(15):3718. doi: 10.3390/cancers14153718
5-FU 5-fluorouracil
ADCs antibody-drug conjugates
BRAF
CEP17
v-raf murine sarcoma viral oncogene homolog B1
centromere enumeration probe for chromosome 17
CNS central nervous system
CRC colorectal cancer
ctDNA circulating tumor DNA
EGF
EGFR
EREG
epidermal growth factor
epidermal growth factor receptor
epiregulin
ESMO European Society of Medical Oncology
FISH fluorescence in situ hybridization
FOLFIRI 5-fluouracil/leucovorin/irinotecan
FOLFOX 5-fluouracil/leucovorin/oxaliplatin
FOLFOXIRI 5-fluouracil/leucovorin/oxaliplatin/irinotecan
HER2 human epidermal growth factor receptor 2
IHC immunochemistry
LV leucovorin
m
MAPK
month
mitogen-activated protein kinase
mCRC metastatic colorectal cancer
mPFS median progression-free survival
NCCN National Comprehensive Cancer Network
NGS next-generation sequencing
NK natural killer
NTRK neurotrophic tyrosine receptor kinase
ORR overall response rates
OS
PI3K
overall survival
phosphoinositide 3-kinase
PFS
PTEN
progression-free survival
phosphatase and tensin homolog
QT chemotherapy
RAS
RTK
STAT
rat sarcoma virus
receptor tyrosine kinase
signal transducer and activator of transcription
T-DM1 trastuzumab emastine
TD trastuzumab deruxtecan
TKIs tyrosine kinase inhibitors
VEGF anti-vascular endothelial growth factor
WT wild-type